Novartis to request re-examination of serelaxin (RLX030) in acute heart ... FiercePharma Basel, January 24, 2014 - Novartis announced today it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure by the Committee for Medicinal ... |
